Pyrotinib with chemotherapy may improve outcomes in patients with pretreated HER2-positive breast cancer
Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib (Tykerb) plus capecitabine, according to updated
Read More